

1           **Incidence and Progression of Foot Osteoarthritis in a Longitudinal**  
2           **Cohort: the Johnston County Osteoarthritis Project**

3  
4           Rami Eltaraboulsi<sup>a,b</sup>, Amanda E. Nelson<sup>a,c</sup>, Carolina Alvarez MS<sup>a</sup>, Jordan B. Renner MD<sup>a,d</sup>,  
5           Catherine Bowen PhD, MSc<sup>e</sup>, Lucy S. Gates PhD<sup>e</sup>, Yvonne M. Golightly PT, PhD<sup>a,f</sup> ✉

6  
7           <sup>a</sup>Thurston Arthritis Research Center, University of North Carolina, Chapel Hill, NC, USA

8           <sup>b</sup>Arthritis and Rheumatism Associates, P.C., Olney, MD, USA

9           <sup>c</sup>Division of Rheumatology, Allergy and Immunology, Department of Medicine, University of  
10          North Carolina, Chapel Hill, NC, USA

11          <sup>d</sup>Department of Radiology, University of North Carolina, Chapel Hill, NC, USA

12          <sup>e</sup>School of Health Sciences, University of Southampton, Southampton, United Kingdom

13          <sup>f</sup>College of Allied Health Professions, University of Nebraska Medical Center, Omaha, NE, USA

14  
15          Short title: Incidence and Progression of Foot Osteoarthritis

16  
17          Corresponding author:

18          Yvonne M. Golightly, PT, PhD, College of Allied Health Professions,

19          University of Nebraska Medical Center, 98400 Nebraska Medical Center, Omaha, NE 68198

20          Email address: [ygolightly@unmc.edu](mailto:ygolightly@unmc.edu)

21  
22          Keywords: foot, osteoarthritis, pain, cohort, epidemiology

23

## 24 **Abstract**

25 *Introduction:* To examine the incidence and progression of foot osteoarthritis (OA), as well as  
26 associated factors, in a community-based cohort.

27 *Methods:* Baseline (2013-2015) and follow-up (2016-2018) foot radiographs were available for  
28 541 participants (71% women, mean age 69 years; 35% Black, 53% with obesity). The LaTrobe  
29 Foot Atlas was used to examine osteophytes (OP, score 0-3) and joint space narrowing (JSN,  
30 score 0-3) at 5 joint sites. Incident foot radiographic OA (rOA) was a baseline score  $<2$  OP and  
31 JSN in all 5 joints with  $\geq 2$  OP or JSN at follow-up in any of the joints. Progression was a  
32 worsening OP or JSN score in a joint with baseline foot rOA. At baseline and follow-up,  
33 participants reported presence/absence of foot symptoms and completed the Foot and Ankle  
34 Outcome Score (FAOS) for each foot. Joint-based logistic regression models with generalized  
35 estimating equations were used to examine associations (adjusted odds ratio [aOR], 95%  
36 confidence interval [CI]) of foot rOA incidence and progression and with covariates.

37 *Results:* Among 928 feet without baseline rOA, 4% developed incident foot rOA (2% of those  
38 developed symptoms). Among 154 feet with baseline foot rOA, 55% had radiographic  
39 progression (16% of those had symptoms). Women and those with higher body mass index  
40 (BMI) were more likely to have incident foot rOA (aOR [95% CI] = 4.10 [1.22, 13.8] and 1.60  
41 [1.31, 1.97], respectively); history of gout was associated with incidence or progression of foot  
42 rOA (2.75 [1.24, 6.07]). BMI was associated with worse scores on all FAOS subscale (aORs range  
43 1.21-1.40).

44 *Conclusion:* Progression of foot rOA is common but not necessarily related to worsening  
45 symptoms. BMI may be a modifiable risk factor for foot OA.

## 46 **Introduction**

47 Osteoarthritis (OA) is the most common joint disease worldwide and is a major source of pain,  
48 disability, and healthcare expenditure [1]. OA affects about 15% of the population and  
49 commonly involves the hips, knees, and hands [2]. Foot OA has been described in the literature  
50 [3-9] but to a lesser extent than other joint sites. Foot involvement is of interest because foot  
51 pain has been identified as an independent risk factor for impaired balance, increased risk of  
52 falling, and locomotor disability [10]. Roughly one in six adults aged 50 years and older have  
53 symptomatic radiographic OA of the foot [11].

54 Previously, foot OA has been difficult to study due to a lack of a formal radiographic grading  
55 system as well as limited joint assessments [11, 12]. The Kellgren-Lawrence grading system [13]  
56 is one of the most widely used tools in OA classification, particularly for the knees [14], and has  
57 been used for classifying foot OA, although Menz et al. [15] state that it places too much  
58 importance on osteophyte formation. Therefore, to better classify foot OA by including specific  
59 grading of joint space narrowing, the La Trobe Atlas was created. In addition to scoring five  
60 joints within the foot and incorporating both osteophytes (OP) and joint space narrowing (JSN),  
61 it advocates for anteroposterior and lateral radiographic views of each joint since some  
62 features of OA, particularly at the midfoot, may be missed with only one view [11, 15].

63 In the literature, data regarding incidence and progression of foot OA are lacking, with two  
64 studies reporting on the incident first metatarsophalangeal joint (1<sup>st</sup> MTP) OA only [16, 17] and  
65 no known studies of incidence or progression of midfoot OA. Knowledge regarding this area is  
66 important given the significant consequences of OA at other joint sites. OA contributes to pain,  
67 decreased quality of life, and disability [18]. Understanding symptoms, risk factors, and how to  
68 objectively follow disease progression over time remains of high interest. Sociodemographic  
69 and clinical characteristics, particularly those that are easy to ascertain from medical records or  
70 questionnaires, may help with advancing the ability to identify individuals at high risk for  
71 incident or progressive foot OA. Based on prior studies of foot OA, potential factors include  
72 older age, female sex, higher body mass index (BMI), and history of foot injury [4, 11, 19]. Gout  
73 and OA are linked; the relationship may be bidirectional and influenced by shared risk factors of

74 age, sex, and obesity [20]. Among those who already have foot OA and pain, being on work  
75 disability or using medications for pain may be early signs of those who may have more severe  
76 disease or are at risk for progression. Understanding associated factors that are easy to assess  
77 could help guide treatment and preventive measures for foot OA. The objectives of this study  
78 were to describe the incidence and progression of foot radiographic OA, symptoms, and foot-  
79 related outcomes and associated factors in a large community-based cohort.

## 80 **Methods**

### 81 *Study Population*

82 This cohort study is reported as per Strengthening the Reporting of Observational studies in  
83 Epidemiology (STROBE) guidelines. Data were obtained from the Johnston County OA Project  
84 (JoCoOA), a prospective community-based cohort of residents of Johnston County, North  
85 Carolina who identified as Black or White and were at least 45 years old at enrollment (Original  
86 Cohort 1991-1997, Enrichment Cohort 2003-2004). Details of the JoCoOA are described  
87 elsewhere [21-24]. All participants completed written informed consent, and the Institutional  
88 Review Board at the University of North Carolina, Chapel Hill has continuously approved the  
89 JoCoOA (IRB #92-0583). For the present analysis, we utilized data from two study visits that  
90 included collection of foot radiographs: 2013-2015 (referred to as baseline for the present  
91 analysis) and 2016-2018 (follow-up).

### 92 *Incident and Progressive Foot Radiographic OA*

93 Weight-bearing radiographs of the feet were obtained in dorsoplantar and lateral views.  
94 Radiographs were assessed by an expert musculoskeletal radiologist (JBR). The La Trobe Foot  
95 Atlas was used to examine osteophytes (OP, score 0-3) and joint space narrowing (JSN, score 0-  
96 3) in five specified joints: 1<sup>st</sup> MTP, 1<sup>st</sup> & 2<sup>nd</sup> cuneo-metatarsal, navicular-1<sup>st</sup> cuneiform, and talo-  
97 navicular joints. Because there is no standard approach for using the La Trobe Atlas to define  
98 changes in foot OA over time, our research team, led by experts in foot radiography (JBR), foot  
99 OA research (YMG, LG, CB), and longitudinal analyses of OA cohorts (YMG, AEN, CA, LG, CB)  
100 developed an algorithm for determining clinically relevant definitions for incident and

101 progressive foot OA. Baseline foot OA was defined as score of  $\geq 2$  in OP or JSN in at least one  
102 joint. Incident foot radiographic OA (rOA) was defined as baseline score  $< 2$  OP and JSN in all 5  
103 joints with  $\geq 2$  OP or JSN at follow-up in any of the five joints. Progression was defined as a  
104 worsening score of OP or JSN by follow-up in any of the 5 foot joints for a foot that already had  
105 rOA in at least one foot joint (e.g., new  $\geq 2$  OP or JSN in a foot joint that did not have rOA at  
106 baseline but another foot joint in that foot had rOA at baseline; worsening OP or JSN score in a  
107 foot joint that had  $\geq 2$  OP or JSN baseline).

#### 108 *Foot Symptoms*

109 Using a standard question from the Behavioral Risk Factor Surveillance System to assess chronic  
110 joint symptoms, participants were asked at baseline and follow-up to rate their foot symptoms  
111 (i.e., pain, aching, or stiffness) in each foot as 0-10 (none to extreme) on most days of any  
112 month in the past 12 months. Foot symptoms worsening was defined as an increase in the foot  
113 symptoms rating from baseline to follow-up.

#### 114 *Foot and Ankle Outcome Score*

115 The Foot and Ankle Outcome Score (FAOS), a 42-item questionnaire assessing patient relevant  
116 outcomes in five subscales (pain, other symptoms, activities of daily living [ADL], sport and  
117 recreation function, foot and ankle-related quality of life [QOL]), was obtained and scored by  
118 subscale (0-100 = extreme problems to no problems). Worsening of each FAOS subscale was  
119 defined as any decrease in the score from baseline to follow-up. A previous study  
120 demonstrated sufficient reliability and validity of the FAOS in the JoCoOA, with high internal  
121 consistency for all subscales; high test-retest reliability for pain, ADL, and QOL subscales; and  
122 moderate convergent validity [25].

#### 123 *Demographic and Clinical Characteristics*

124 The following demographic and clinical characteristics were included in analyses because of  
125 their potential associations with foot OA and symptoms. Participants reported their age  
126 (continuous), sex (men/women), and race (Black/White). For these analyses, age was a

127 continuous variable. Height was measured using a calibrated stadiometer, and weight was  
128 measured using a balance-beam scale. BMI was calculated as body weight in kilograms divided  
129 by the square of height in meters. Work disability was defined as self-report of currently  
130 receiving work disability payments from either government or disability insurance. Non-  
131 steroidal anti-inflammatory drug (NSAID) use was defined as current use excluding low-dose  
132 aspirin (81 mg daily). History of gout in the left or right foot was defined as self-report of being  
133 told by a physician of having gout. Prior foot injury in the left or right foot was defined as a  
134 history of an injury to the foot that limited the participant's ability to walk for at least two days.

### 135 *Analyses*

136 Descriptive statistics of counts and percentages for categorical variables and means and  
137 standard deviation (SD) for continuous variables were produced. For variables at the person-  
138 level, these were provided out of the total number of participants. For variables at the foot-  
139 level, these were provided out of the total number of feet [left and right]. Foot-level logistic  
140 regression models with generalized estimating equations (GEE) were used to examine  
141 associations of foot rOA incidence and progression and covariates of age, sex, race, BMI, work  
142 disability, NSAID use, gout, and foot injury. Laterality was accounted for in models for the foot-  
143 level variables of gout and injury (e.g., left foot injury corresponded to left foot OA outcomes).  
144 For adjusted models, we selected a consistent set of covariates to control for based on prior  
145 knowledge of their associations with the independent and dependent variables, as well as  
146 statistical assessment that supported them as likely confounders across models. For each  
147 model, two-way interactions between covariates and baseline foot rOA status were assessed at  
148 a 0.10 alpha level, and adjusted odds ratios and 95% confidence intervals (aOR [95% CI]) were  
149 shown by baseline status if significant. Otherwise, overall associations were shown.

150 Assumptions under logistic regression were met with 1) dependency among feet addressed by  
151 use of GEE methods in the models, 2) a binary response for each outcome following a binomial  
152 distribution, 3) for continuous predictors linearity assessed by testing non-linear polynomials,  
153 and 4) assessment of none or minimal multicollinearity by verifying that the largest condition

154 index be less than 30 [26]. Analyses were conducted using the statistical software package SAS  
155 version 9.4 (SAS Institute Inc., Cary, NC).

## 156 **Results**

157 Of the 864 participants with foot data at baseline, 323 (37%) did not attend the follow-up visit.  
158 Compared to those who attended the follow-up visit, those who did not attend were more  
159 likely to be older, receiving work disability, men, or have lower FAOS scores, but were not  
160 notably different based on other measured factors (Supplementary Table). Out of a total of 582  
161 participants who attended both research clinic visits, 41 participants were excluded due to  
162 missing foot radiograph data at baseline or follow up, leaving 541 participants (1082 feet) with  
163 data available for analysis (Figure 1). Compared to the 541 participants with foot radiograph  
164 data, the 41 participants without these data tended to be older (73 vs 69 years) with a higher  
165 BMI (35 vs 31 kg/m<sup>2</sup>) and more foot pain (39% vs 19% with foot pain at baseline). There were  
166 no notable differences by sex, race, or education. The mean time between study visits was 3.5  
167 years (standard deviation  $\pm$  0.7 years, range 2-5 years).

168 Over 22% of participants had foot rOA at baseline. The mean age of participants was 69 years  
169 and 71% were women, 35% were Black, and 53% had obesity (mean BMI 31 kg/m<sup>2</sup>, Table 1).  
170 Approximately 60% of participants had used NSAIDs within the last two weeks and 22%  
171 reported work disability. Compared to those without foot rOA at baseline, participants with  
172 foot rOA were more likely to be women, identify as Black, and have a higher BMI. History of  
173 gout and prior foot injury were observed in about 6% and 2% of feet, respectively. Of the 1082  
174 feet in this study, 154 (14%) met the definition for rOA at baseline. Among feet with rOA at  
175 baseline, the most affected joint was the 1<sup>st</sup> MTP (42%) followed by the talo-navicular (31%).  
176 Foot symptoms were reported among 20% of individuals with foot rOA (24/120); similarly, foot  
177 symptoms occurred in 20% of feet with rOA (31/154).

178 Among the 928 feet with no rOA at baseline, roughly 4% of feet developed incident foot rOA  
179 and 1.5% had incident rOA with symptoms at follow up (Table 2). Of the 154 feet with rOA at  
180 baseline, over half (55%) had rOA worsening and 16% had rOA worsening with symptoms at

181 follow up. Compared to feet without baseline rOA, feet with baseline rOA had higher  
182 proportions of worsening foot symptoms (19.5% vs. 13.8%) and FAOS subscale scores (ranges  
183 33.1-43.5% vs. 26.3-34.4%).

184 Women and those with higher BMI were more likely to develop incident foot rOA (aOR [95%CI]  
185 = 4.10 [1.22, 13.8] and 1.60 [1.31, 1.97], respectively; Table 3). Self-reported history of gout was  
186 associated with increased odds of incidence or progression of foot rOA (aOR [95%CI] = 2.75  
187 [1.25, 6.07]). Black race, compared to White, was less likely to be associated with incidence or  
188 progression foot rOA with new foot symptoms at follow up (aOR [95%CI] = 0.37 [0.15, 0.90]).  
189 Among those without baseline foot rOA, having a higher BMI was associated with significantly  
190 increased odds of incident foot rOA with foot symptoms at follow up (aOR [95%CI] = 1.81 [1.39,  
191 2.36]). A history of foot injury was strongly associated with incidence or progression of foot rOA  
192 with symptoms at follow-up (aOR [95%CI] =4.99 [1.57, 15.9]).

193 Among those with foot rOA at baseline, worsening of foot symptoms was less likely with older  
194 age (aOR [95%CI] = 0.70 [0.50, 0.99], Table 3). Regardless of foot rOA status at baseline, work  
195 disability was associated with worsening of foot symptoms (aOR [95%CI] = 1.81 [1.07, 3.04],  
196 Table 3) and FAOS worsening, particularly for pain, ADL, and sports and recreation subscales  
197 (aOR [95%CI] = 2.08 [1.26, 3.43], 2.09 [1.33, 3.27], and 2.19 [1.35, 3.55], respectively, Table 4).  
198 A higher BMI was associated with increased odds for worsening of all FAOS subscales (aORs  
199 range 1.21-1.40 with 95%CI between 1.04 and 1.66). Older age was not associated with  
200 worsening of FAOS symptoms or QOL. In fact, among those with baseline foot rOA, older age  
201 was associated with lower odds of worsening in FAOS pain and ADL subscales (aOR [95%CI]=  
202 0.74 [0.58, 0.96] and 0.77 [0.60, 0.98], respectively). History of gout was associated with  
203 increased odds of worsening for FAOS ADL and sports and recreation subscales (aOR [95%CI]=  
204 1.59 [1.09, 2.31] and 1.47 [1.10, 1.96], respectively), and history of foot injury was associated  
205 with increased odds of worsening on the FAOS ADL subscale (aOR [95%CI]= 2.57 [1.18, 5.61]).

206



## 207 **Discussion**

208 In this large community-based cohort, we aimed to estimate the incidence and progression of  
209 foot rOA, foot symptoms, and foot-related outcomes, as well as examine associations with  
210 factors that may help identify those at risk for the occurrence or progression of these  
211 conditions. In this study, the incidence of foot rOA over 3.5 years was low (<5%) with few (<2%)  
212 having foot symptoms at follow-up. Progression of foot rOA was observed in the majority of  
213 those with foot rOA (55%) but was not necessarily associated with worsening symptoms (16%).  
214 Worsening foot symptoms and FAOS subscale scores were higher among feet with baseline rOA  
215 compared to those without rOA. Compared to those without foot rOA, those with foot rOA at  
216 baseline were more likely to be women, have a higher BMI, and identify as Black. Women and  
217 individuals with a higher BMI had higher odds of incident foot rOA, while self-reported history  
218 of gout was associated with higher odds of both incidence and progression of foot rOA. Foot  
219 injury was linked to higher odds of incidence and progression of foot rOA with symptoms at  
220 follow up. Higher BMI was associated with increased odds for worsening of foot symptoms and  
221 of all FAOS subscales.

222 Nearly 1 in 7 feet had rOA at baseline, and of the joints affected, foot rOA was most commonly  
223 seen in the 1st MTP, followed by talo-navicular and navicular-1<sup>st</sup> cuneiform joints; this  
224 observation is somewhat consistent with other cohorts [27]. Other studies have shown the 1st  
225 MTP to be the most common foot joint site for OA using the Kellgren-Lawrence grading system  
226 with a focus on forefoot involvement as opposed to the La Trobe Atlas [11], which focuses on  
227 the medial column of the foot based on the developers' identification of the joints most  
228 commonly affected by OA. Our results differ from prior reports that found the 2nd  
229 cuneometatarsal joint to be the second most commonly affected foot joint [7, 15]. Variation in  
230 results may be due to differences in the study samples; prior studies appeared to recruit those  
231 with foot pain or clinical samples whereas JoCoOA enrolled from a general, bi-racial, rural  
232 population without regard to pain or disease status [21] . A cross-sectional study from the  
233 United Kingdom (UK) highlighted the importance of identifying midfoot OA [28]. In that study,  
234 midfoot OA was divided into central midfoot (2<sup>nd</sup> cuneo-metatarsal) and medial midfoot (1<sup>st</sup>

235 cuneo-metatarsal, navicular-1<sup>st</sup> cuneiform, and talo-navicular). Having both central and medial  
236 involvement was associated with increased pain scores, dorsally located midfoot pain, hallux  
237 valgus, flatter foot posture and loss of medial arch height. Likewise, another UK study identified  
238 that participants with a polyarticular phenotype with midfoot OA involvement tended to have  
239 more severe pain and disability compared to isolated 1<sup>st</sup> MTP OA [29]. Although the 1st MTP is  
240 commonly involved, this information highlights that midfoot OA may be underrecognized in the  
241 literature.

242 Incidence of foot OA has not been widely reported. For 1st MTP OA, the Clearwater OA Study  
243 [17] reported incidence of 25-27% over a seven-year period (N=1592), and the Chingford Study  
244 [16] reported incidence of 13.5% and 8.3% among women over a 19-year period in the right  
245 and left 1<sup>st</sup> MTP, respectively (N=193). The incidence of foot rOA in our study may be lower due  
246 to a shorter follow-up time and differences in population (i.e., Clearwater OA Study enrolled  
247 volunteers and was not population-based; Chingford Study included only women). Those with  
248 greater risk for health problems may be more likely to volunteer for a project like the  
249 Clearwater OA Study, thus limiting generalizability of results. Radiographic progression of foot  
250 OA has not been widely reported either. One prospective analysis of a community cohort  
251 examined foot symptoms over an 18-month period and found that symptoms improved across  
252 all foot OA subtypes [30]. Together with our findings, this may suggest that progression of foot  
253 rOA does not always correspond to pain.

254 In the present study, the major factors associated with foot rOA with symptoms, or  
255 symptomatic foot OA, included BMI and prior foot injury. Increases in BMI by 5 kg/m<sup>2</sup> were  
256 associated with nearly twice the odds of symptomatic foot OA. A study from the UK showed  
257 that risk factors for symptomatic foot OA included age above 75 years, female sex, manual  
258 occupation, and obesity [6]. Although we did not see an association between age and  
259 worsening foot rOA, this may be due to a lack of JoCoOA participants at this study time point  
260 who were younger than 55 years of age. Studies of OA affecting other joint sites have reported  
261 similar associated factors. Reyes et al.[31] showed that both knee and hip OA were associated  
262 with increased BMI. The knee was more strongly associated with obesity than the hip, and

263 depending upon the BMI category, knee OA incidence increased up to 4.7 times. These results  
264 emphasize the importance of a healthy weight and weight loss for those with obesity to  
265 manage OA and extend this to management of foot OA.

266 History of foot injury was not statistically significantly associated with incidence or progression  
267 of foot rOA in this study, but the odds were 2.75 times higher compared to no injury. Although  
268 the foot injury was uncommon (2.4% at baseline), it was strongly associated with symptomatic  
269 foot OA incidence and progression, with nearly five times higher odds than no injury. Prior foot  
270 injury also was linked to worsening physical function (FAOS ADL). Little has been published on  
271 the relationship between injury and symptomatic OA of the foot in large cohort studies[4, 19].  
272 In the Clinical Assessment Study of the Foot, a history of foot or ankle injury was related to  
273 symptomatic midfoot OA (aOR 1.60, 95% CI 0.98, 2.60), although this result was not statistically  
274 significant [19]. The current study provided estimates of the longitudinal association between  
275 foot injury and OA in a general population of middle age to older adults who were not selected  
276 based on foot pain. Although the period between study visits was somewhat short (~3.5 years),  
277 the results suggest a strong link between injury and symptomatic OA outcomes at the foot,  
278 similar to associations seen between injury and OA at the knee and ankle [32].

279 Self-report of history of gout was significantly associated with incidence or progression of foot  
280 rOA, which adds to our understanding of the complex relationship between gout and OA at the  
281 foot. Prior studies have suggested that the presence of OA may predispose a joint to gout [33],  
282 with monosodium urate crystals from hyperuricemia more often being deposited in OA  
283 affected joints than healthy joints. For example, in a study of 164 individuals with acute gout  
284 flares, the odds of OA at the 1<sup>st</sup> MTP and midfoot were 2-3 times higher compared those  
285 without gout flares [34]. In a cross-sectional study of individuals with foot pain, the odds of  
286 having at least three foot joints affected by rOA was four times higher among those with than  
287 without gout (aOR [95%CI] = 4.00 [0.99, 16.10]) [35]. Alternatively, OA may occur more often  
288 among joints damaged by gout flares. Based on evidence from the literature, a bidirectional  
289 relationship is highly likely [20, 36].

290 A higher BMI also was a risk factor for poorer scores on the FAOS. This observation held true for  
291 all patient-related aspects, including symptoms, pain, ADL, sports and recreation, and quality of  
292 life. Prior foot injury and self-reported history of gout also were linked to worse FAOS subscales  
293 related to function (activities of daily living, sports and recreation). The FAOS has not been  
294 broadly utilized in foot OA. Historically, FAOS has been used to characterize outcomes in those  
295 with lateral ligament reconstruction, hallux valgus, and adult acquired flatfoot deformity [37].  
296 Mani et al. [37] looked at FAOS in patients with ankle OA and compared this to another widely  
297 used questionnaire, the Short-Form 12 version 2 (SF-12). They concluded that the FAOS was not  
298 highly reliable across all five domains but may be helpful when assessing pain, activities of daily  
299 living and quality of life. A previous study of the JoCoOA showed satisfactory reliability and  
300 validity of the FAOS in this cohort. [25]

301 Older age was less likely to be associated with worsening of foot symptoms (pain, aching, and  
302 stiffness), pain (FAOS pain), and physical function (FAOS ADL) among feet with baseline rOA.  
303 Although we cannot be certain based on our available data, potential loss of pain sensitivity for  
304 lower intensity pain and elevated pain tolerance thresholds that can occur with aging [38]  
305 could be playing a role in our results. Among adults with foot rOA, those who are older may be  
306 less likely to detect pain changes over time or may be able to better tolerate those changes  
307 than younger adults. Those who were younger in our cohort were at least 55 years of age at  
308 baseline and were in a period of life where they were likely more mobile and active than older  
309 adults. Thus, increasing pain and declines in physical function could be more detectable for  
310 these adults than for older adults. Future studies examining pain perception may elucidate  
311 associations between aging and foot pain and impaired foot-related function.

312 Strengths of this study include the use of data from a large community-based cohort that did  
313 not select for individuals with foot joint concerns or any clinical diagnoses. By following  
314 participants longitudinally over an average of 3.5 years, we were able to calculate incidence and  
315 progression of foot rOA. For consistency, our radiographs were obtained by a single expert  
316 technologist and read in a standardized manner, with one musculoskeletal radiologist (JBR)  
317 with decades of experience interpreting the films for the JoCoOA. Having a single reader also

318 may be a limitation, but our radiologist has a long record in the JoCoOA of excellent intra- and  
319 inter-rater reliability for radiographic reads (weighted kappas  $\geq 0.90$ ) [39, 40]. A limitation to  
320 our study was the inclusion of mostly older adults (mean age 69) and therefore less  
321 generalizability to younger populations. Additionally, there was study attrition, which occurs in  
322 most longitudinal studies and may contribute to bias since those with poorer health are less  
323 likely to return for follow-up visits. Some items of our study were self-reported, such as gout or  
324 foot injury, and our data on gout did not specify the joints affected by gout. Also, few  
325 participants had a history of gout or foot injury, and accordingly, it was not feasible to  
326 sufficiently determine their associations with OA of specific regions of the foot (e.g., 1<sup>st</sup> MTP,  
327 midfoot). We utilized an approach to defining incidence and progression of foot rOA based on  
328 established strategies for defining rOA, and future studies should examine these definitions and  
329 explore variations of these definitions across diverse samples. Considering that not all injuries  
330 are medically attended and thus not available in the medical record, self-report would lessen  
331 misclassification of foot injury. Given the paucity of information regarding foot OA, this study  
332 provides important insights into associated risk factors for foot OA and strategies for future  
333 research.

334 In summary, progression of foot rOA is relatively common, although it is not necessarily related  
335 to worsening symptoms. The factors that may be important for foot OA development include  
336 sex, BMI, and history of gout. Given the strong association of foot rOA and FAOS with higher  
337 BMI, BMI may be a modifiable risk factor for the development of foot rOA, similar to other  
338 weight-bearing joints such as the knee. Strategies for prevention of foot injuries are likely  
339 important for symptomatic foot rOA. Further studies should determine if interventions, such as  
340 weight loss, could lead to better symptom control in foot OA and should examine the  
341 association of foot OA with OA at other joint sites.

342

343 **Acknowledgement**

344 The authors are grateful to the research staff and participants in the JoCoOA.

345 **Statement of ethics**

346 This study used an existing data from the JoCoOA. All participants completed written informed  
347 consent. The JoCoOA has been continuously approved by the University of North Carolina at  
348 Chapel Hill Institutional Review Board #92-0583.

349 **Conflict of Interest Statement**

350 The authors have no conflicts of interest to declare.

351 **Funding Sources**

352 Supported by the Centers for Disease Control and Prevention/Association of Schools of Public  
353 Health (grants S-043, S-1734, S-3486, and U01-DP-003206), the National Institutes of  
354 Health/National Institute of Arthritis and Musculoskeletal and Skin Diseases (grants P60  
355 AR30701, P60 AR049465, P60 AR064166, P30 AR072580, U01 DP006266, and R01 AR067743).  
356 The funders had no role in the design, data collection, data analysis, and reporting of this study.

357 **Author Contributions**

358 Conception and design: RE, AEN, CA, JBR, CB, LSG, YMG; Acquisition of data: JBR, YMG; Analysis  
359 and interpretation of data: RE, AEN, CA, JBR, CB, LSG, YMG. Drafting the manuscript: RE, AEN,  
360 CA, YMG; Critical revisions for important intellectual content: RE, AEN, CA, JBR, CB, LSG, YMG.  
361 Final approval of the version to be published: all. YMG is accountable for all aspects of the  
362 work.

363 **Data Availability Statement**

364 The datasets that were used and analyzed during the current study are not publicly available  
365 because they contain identifying information that could compromise the privacy of research  
366 participants. The data are available upon reasonable request from the co-Principal Investigators  
367 of the JoCoOA, Dr. Amanda E. Nelson ([amanda\\_nelson@med.unc.edu](mailto:amanda_nelson@med.unc.edu)) and Dr. Yvonne M.  
368 Golightly (corresponding author, [ygolightly@unmc.edu](mailto:ygolightly@unmc.edu)).

369

370 **References**

- 371 1. Glyn-Jones S, Palmer AJR, Agricola R, Price AJ, Vincent TL, Weinans H, Carr AJ:  
372 Osteoarthritis. *The Lancet* 2015, 386(9991):376-387.
- 373 2. Johnson VL, Hunter DJ: The epidemiology of osteoarthritis. *Best Pract Res Clin*  
374 *Rheumatol* 2014, 28(1):5-15.
- 375 3. Arnold JB, Halstead J, Grainger AJ, Keenan AM, Hill CL, Redmond AC: Foot and Leg  
376 Muscle Weakness in People With Midfoot Osteoarthritis. *Arthritis Care Res (Hoboken)*  
377 2021, 73(6):772-780.
- 378 4. Flowers P, Nelson AE, Hannan MT, Hillstrom HJ, Renner JB, Jordan JM, Golightly YM:  
379 Foot Osteoarthritis Frequency and Associated Factors in a Community-Based Cross-  
380 Sectional Study of White and African American Adults. *Arthritis Care Res (Hoboken)*  
381 2021, 73(12):1784-1788.
- 382 5. Golightly YM, Hannan MT, Nelson AE, Hillstrom HJ, Cleveland RJ, Kraus VB, Schwartz TA,  
383 Goode AP, Flowers P, Renner JB *et al*: Relationship of Joint Hypermobility with Ankle and  
384 Foot Radiographic Osteoarthritis and Symptoms in a Community-Based Cohort. *Arthritis*  
385 *Care Res (Hoboken)* 2019, 71(4):538-544.
- 386 6. Peat G, Rathod-Mistry T, Paskins Z, Marshall M, Thomas MJ, Menz HB, Nicholls E, Myers  
387 H, Duncan R, van der Windt DA *et al*: Relative prevalence and distribution of knee, hand  
388 and foot symptomatic osteoarthritis subtypes in an English population. *Musculoskeletal*  
389 *Care* 2020, 18(2):219-224.
- 390 7. Roddy E, Thomas MJ, Marshall M, Rathod T, Myers H, Menz HB, Thomas E, Peat G: The  
391 population prevalence of symptomatic radiographic foot osteoarthritis in community-

- 392 dwelling older adults: cross-sectional findings from the clinical assessment study of the  
393 foot. *Ann Rheum Dis* 2015, 74(1):156-163.
- 394 8. van Saase JL, van Romunde LK, Cats A, Vandenbroucke JP, Valkenburg HA: Epidemiology  
395 of osteoarthritis: Zoetermeer survey. Comparison of radiological osteoarthritis in a  
396 Dutch population with that in 10 other populations. *Ann Rheum Dis* 1989, 48(4):271-  
397 280.
- 398 9. Wilder FV, Barrett JP, Farina EJ: The association of radiographic foot osteoarthritis and  
399 radiographic osteoarthritis at other sites. *Osteoarthritis Cartilage* 2005, 13(3):211-215.
- 400 10. Thomas MJ, Roddy E, Zhang W, Menz HB, Hannan MT, Peat GM: The population  
401 prevalence of foot and ankle pain in middle and old age: a systematic review. *Pain* 2011,  
402 152(12):2870-2880.
- 403 11. Roddy E, Menz HB: Foot osteoarthritis: latest evidence and developments. *Ther Adv*  
404 *Musculoskelet Dis* 2018, 10(4):91-103.
- 405 12. Trivedi B, Marshall M, Belcher J, Roddy E: A systematic review of radiographic  
406 definitions of foot osteoarthritis in population-based studies. *Osteoarthritis Cartilage*  
407 2010, 18(8):1027-1035.
- 408 13. Kellgren JH, Lawrence JS: Radiological assessment of osteo-arthrosis. *Ann Rheum Dis*  
409 1957, 16(4):494-502.
- 410 14. Kohn MD, Sassoon AA, Fernando ND: Classifications in Brief: Kellgren-Lawrence  
411 Classification of Osteoarthritis. *Clin Orthop Relat Res* 2016, 474(8):1886-1893.



- 412 15. Menz HB, Munteanu SE, Landorf KB, Zammit GV, Cicuttini FM: Radiographic evaluation  
413 of foot osteoarthritis: sensitivity of radiographic variables and relationship to symptoms.  
414 *Osteoarthritis Cartilage* 2009, 17(3):298-303.
- 415 16. Bowen C, Gates L, McQueen P, Daniels M, Delmestri A, Drechsler W, Stephensen D,  
416 Doherty M, Arden N: Natural History of Radiographic First Metatarsophalangeal Joint  
417 Osteoarthritis: A Nineteen-Year Population-Based Cohort Study. *Arthritis Care Res*  
418 *(Hoboken)* 2020, 72(9):1224-1230.
- 419 17. Mahiquez MY, Wilder FV, Stephens HM: Positive hindfoot valgus and osteoarthritis of  
420 the first metatarsophalangeal joint. *Foot Ankle Int* 2006, 27(12):1055-1059.
- 421 18. Hawker GA: Osteoarthritis is a serious disease. *Clin Exp Rheumatol* 2019, 37 Suppl  
422 120(5):3-6.
- 423 19. Thomas MJ, Peat G, Rathod T, Marshall M, Moore A, Menz HB, Roddy E: The  
424 epidemiology of symptomatic midfoot osteoarthritis in community-dwelling older  
425 adults: cross-sectional findings from the Clinical Assessment Study of the Foot. *Arthritis*  
426 *Res Ther* 2015, 17(1):178.
- 427 20. Neogi T, Krasnokutsky S, Pillinger MH: Urate and osteoarthritis: Evidence for a reciprocal  
428 relationship. *Joint Bone Spine* 2019, 86(5):576-582.
- 429 21. Golightly YM, Renner JB, Helmick CG, Jordan JM, Nelson AE: Looking back on 30+ years  
430 of the Johnston County Osteoarthritis Project while looking forward with the Johnston  
431 County Health Study: A narrative review. *Osteoarthritis Cartilage* 2024.

- 432 22. Jordan JM: An Ongoing Assessment of Osteoarthritis in African Americans and  
433 Caucasians in North Carolina: The Johnston County Osteoarthritis Project. *Trans Am Clin*  
434 *Climatol Assoc* 2015, 126:77-86.
- 435 23. Hartman EL, Woodard J, Patterson C, Jordan JM: The Johnston County osteoarthritis  
436 project: an illustration of a community-university partnership for population-based  
437 research. *N C Med J* 2007, 68(6):459-462.
- 438 24. Jordan JM, Helmick CG, Renner JB, Luta G, Dragomir AD, Woodard J, Fang F, Schwartz  
439 TA, Abbate LM, Callahan LF *et al*: Prevalence of knee symptoms and radiographic and  
440 symptomatic knee osteoarthritis in African Americans and Caucasians: the Johnston  
441 County Osteoarthritis Project. *J Rheumatol* 2007, 34(1):172-180.
- 442 25. Golightly YM, Devellis RF, Nelson AE, Hannan MT, Lohmander LS, Renner JB, Jordan JM:  
443 Psychometric properties of the foot and ankle outcome score in a community-based  
444 study of adults with and without osteoarthritis. *Arthritis Care Res (Hoboken)* 2014,  
445 66(3):395-403.
- 446 26. Kim JH: Multicollinearity and misleading statistical results. *Korean J Anesthesiol* 2019,  
447 72(6):558-569.
- 448 27. International F, Ankle Osteoarthritis C, Arnold JB, Bowen CJ, Chapman LS, Gates LS,  
449 Golightly YM, Halstead J, Hannan MT, Menz HB *et al*: International Foot and Ankle  
450 Osteoarthritis Consortium review and research agenda for diagnosis, epidemiology,  
451 burden, outcome assessment and treatment. *Osteoarthritis Cartilage* 2022, 30(7):945-  
452 955.

- 453 28. Arnold JB, Marshall M, Thomas MJ, Redmond AC, Menz HB, Roddy E: Midfoot  
454 osteoarthritis: potential phenotypes and their associations with demographic,  
455 symptomatic and clinical characteristics. *Osteoarthritis Cartilage* 2019, 27(4):659-666.
- 456 29. Rathod T, Marshall M, Thomas MJ, Menz HB, Myers HL, Thomas E, Downes T, Peat G,  
457 Roddy E: Investigations of Potential Phenotypes of Foot Osteoarthritis: Cross-Sectional  
458 Analysis From the Clinical Assessment Study of the Foot. *Arthritis Care Res (Hoboken)*  
459 2016, 68(2):217-227.
- 460 30. Downes TJ, Chesterton L, Whittle R, Roddy E, Menz HB, Marshall M, Thomas MJ:  
461 Symptomatic Course of Foot Osteoarthritis Phenotypes: An 18-Month Prospective  
462 Analysis of Community-Dwelling Older Adults. *Arthritis Care Res (Hoboken)* 2018,  
463 70(7):1107-1112.
- 464 31. Reyes C, Leyland KM, Peat G, Cooper C, Arden NK, Prieto-Alhambra D: Association  
465 Between Overweight and Obesity and Risk of Clinically Diagnosed Knee, Hip, and Hand  
466 Osteoarthritis: A Population-Based Cohort Study. *Arthritis Rheumatol* 2016, 68(8):1869-  
467 1875.
- 468 32. Allen KD, Thoma LM, Golightly YM: Epidemiology of osteoarthritis. *Osteoarthritis*  
469 *Cartilage* 2022, 30(2):184-195.
- 470 33. Dalbeth N, Aati O, Kalluru R, Gamble GD, Horne A, Doyle AJ, McQueen FM: Relationship  
471 between structural joint damage and urate deposition in gout: a plain radiography and  
472 dual-energy CT study. *Ann Rheum Dis* 2015, 74(6):1030-1036.
- 473 34. Roddy E, Zhang W, Doherty M: Are joints affected by gout also affected by  
474 osteoarthritis? *Ann Rheum Dis* 2007, 66(10):1374-1377.

- 475 35. Bevis M, Marshall M, Rathod T, Roddy E: The association between gout and radiographic  
476 hand, knee and foot osteoarthritis: a cross-sectional study. *BMC Musculoskelet Disord*  
477 2016, 17:169.
- 478 36. Muehleman C, Li J, Aigner T, Rappoport L, Mattson E, Hirschmugl C, Masuda K,  
479 Rosenthal AK: Association between crystals and cartilage degeneration in the ankle. *J*  
480 *Rheumatol* 2008, 35(6):1108-1117.
- 481 37. Mani SB, Do H, Vulcano E, Hogan MV, Lyman S, Deland JT, Ellis SJ: Evaluation of the foot  
482 and ankle outcome score in patients with osteoarthritis of the ankle. *Bone Joint J* 2015,  
483 97-B(5):662-667.
- 484 38. Lautenbacher S, Peters JH, Heesen M, Scheel J, Kunz M: Age changes in pain perception:  
485 A systematic-review and meta-analysis of age effects on pain and tolerance thresholds.  
486 *Neurosci Biobehav Rev* 2017, 75:104-113.
- 487 39. Jordan JM, Linder GF, Renner JB, Fryer JG: The impact of arthritis in rural populations.  
488 *Arthritis Care Res* 1995, 8(4):242-250.
- 489 40. Kraus VB, Worrell TW, Renner JB, Coleman RE, Pieper CF: High prevalence of  
490 contralateral ankle abnormalities in association with knee osteoarthritis and  
491 malalignment. *Osteoarthritis Cartilage* 2013, 21(11):1693-1699.

492

493

494 **Figure legends**

495 **Fig. 1.** Flow diagram of participants.

496

**Table 1.** Characteristics of the study sample by foot radiographic osteoarthritis (rOA) status at baseline and frequency of outcomes.

Person-Level Characteristics	All participants (n=541)	No Foot rOA at baseline (n=421)	Foot rOA at baseline (n=120)
Age, mean±SD (years)	69.4±6.9	69.2±6.8	70.2±7.3
Women, n, %	382, 70.6%	290, 68.9%	92, 76.7%
Black, n, %	190, 35.1%	139, 33.0%	51, 42.5%
BMI, mean±SD (kg/m <sup>2</sup> )	31.2±6.4	30.6±6.0	33.2±7.5
NSAID use past 2 weeks, n, %	325, 60.1%	248, 58.9%	77, 64.2%
Work disability, n, %	119, 22.0%	89, 21.1%	30, 25.0%
Foot-Level Characteristics	All feet (n=1082)	No Foot rOA at baseline (n=928)	Foot rOA at baseline (n=154)
History of gout, n, %	67, 6.2%	59, 6.4%	8, 5.2%
Prior foot injury, n, %	26, 2.4%	20, 2.2%	6, 3.9%
Foot joints with rOA:			
1 <sup>st</sup> metatarsophalangeal, n, %	64, 5.9%	n/a	64, 41.6%
1 <sup>st</sup> cuneometatarsal, n, %	13, 1.2%	n/a	13, 8.4%
2 <sup>nd</sup> cuneometatarsal, n, %	34, 3.1%	n/a	34, 22.1%
navicular-1 <sup>st</sup> cuneiform, n, %	38, 3.5%	n/a	38, 24.7%
talonavicular, n, %	48, 4.4%	n/a	48, 31.2%

SD=standard deviation; BMI=body mass index; NSAID=nonsteroidal anti-inflammatory drug

**Table 2.** Incidence and progression (%) of foot radiographic OA (rOA) and other outcomes at follow up by baseline foot OA status.

Outcome at follow-up	No baseline foot rOA (n=928)	Baseline foot rOA (n=154)
Foot rOA worsening	41, 4.4%	84, 54.5%
Foot rOA worsening with symptoms	14, 1.5%	25, 16.2%
Foot symptoms worsening	128, 13.8%	30, 19.5%
FAOS* Symptoms worsening	319, 34.4%	67, 43.5%
FAOS Pain worsening	265, 28.6%	53, 34.4%
FAOS ADL worsening	244, 26.3%	61, 39.6%
FAOS Sports and Recreation worsening	268, 28.9%	51, 33.1%
FAOS QOL worsening	293, 31.6%	63, 40.9%

FAOS = Foot and Ankle Outcome Score

**Table 3.** Association (aOR [95% CI]) between covariates and foot rOA and symptoms outcomes, stratified by radiographic osteoarthritis (rOA) status where interactions were significant (n=1082).

Risk Factors	Incidence or progression of foot rOA	Incidence or progression of foot rOA with symptoms at follow-up	Foot symptoms worsening*
Age: 5 years older	1.14 (0.97, 1.34)	1.01 (0.76, 1.35)	n/a
No rOA at baseline	n/a	n/a	1.02 (0.85, 1.23)
rOA at baseline	n/a	n/a	0.70 (0.50, 0.99)
Women vs. Men	n/a	2.35 (0.77, 7.22)	1.58 (0.93, 2.71)
No rOA at baseline	4.10 (1.22, 13.8)	n/a	n/a
rOA at baseline	0.46 (0.19, 1.08)	n/a	n/a
Black vs. White	1.04 (0.64, 1.69)	0.37 (0.15, 0.90)	0.59 (0.35, 1.00)
BMI: 5 kg/m <sup>2</sup> increase	n/a	n/a	1.16 (0.97, 1.38)
No rOA at baseline	1.60 (1.31, 1.97)	1.81 (1.39, 2.36)	n/a
rOA at baseline	1.11 (0.90, 1.36)	1.07 (0.78, 1.47)	n/a
Work disability	0.74 (0.39, 1.42)	1.24 (0.43, 3.63)	1.81 (1.07, 3.04)
NSAID use	1.38 (0.82, 2.31)	1.95 (0.74, 5.14)	1.29 (0.79, 2.10)
History of gout	2.75 (1.25, 6.07)	2.01 (0.68, 5.92)	1.42 (0.81, 2.49)
Foot injury	2.75 (0.73, 10.4)	4.99 (1.57, 15.9)	1.59 (0.61, 4.13)

BMI = body mass index, NSAID = nonsteroidal anti-inflammatory drug

Models adjusted for race, work disability, NSAID use, any foot symptoms at baseline.

\*n=1080



**Table 4.** Association (aOR [95% CI]) for covariates and worsening for each Foot and Ankle Outcome Scale (FAOS) subscale outcomes, stratified by radiographic osteoarthritis (rOA) where interactions were significant (n=1080).

Risk Factors	FAOS Symptoms	FAOS Pain	FAOS-Activities of Daily Living	FAOS Sports and Recreation	FAOS Quality of Life
Age: 5 years older	1.13 (0.99, 1.31)	n/a	n/a	n/a	1.01 (0.89, 1.15)
No rOA at baseline	n/a	1.01 (0.88, 1.16)	1.09 (0.94, 1.26)	1.12 (0.97, 1.29)	n/a
rOA at baseline	n/a	0.74 (0.58, 0.96)	0.77 (0.60, 0.98)	0.89 (0.71, 1.13)	n/a
Women vs. Men	n/a	1.41 (0.93, 2.13)	1.58 (1.04, 2.42)	1.57 (1.01, 2.43)	1.31 (0.89, 1.94)
No rOA at baseline	1.47 (0.95, 2.27)	n/a	n/a	n/a	n/a
rOA at baseline	0.60 (0.26, 1.37)	n/a	n/a	n/a	n/a
Black vs. White	0.95 (0.63, 1.45)	0.87 (0.58, 1.30)	0.82 (0.55, 1.24)	0.72 (0.47, 1.11)	0.69 (0.47, 1.02)
BMI: 5 kg/m <sup>2</sup> increase	1.40 (1.19, 1.66)	1.22 (1.05, 1.41)	1.21 (1.04, 1.41)	1.31 (1.11, 1.54)	1.24 (1.06, 1.44)
Work disability	1.39 (0.85, 2.27)	2.08 (1.26, 3.43)	2.09 (1.33, 3.27)	2.19 (1.35, 3.55)	1.60 (1.02, 2.50)
NSAID use	1.16 (0.78, 1.72)	1.10 (0.76, 1.59)	1.15 (0.79, 1.69)	1.17 (0.78, 1.74)	1.19 (0.84, 1.70)
Gout	0.98 (0.65, 1.47)	0.87 (0.54, 1.40)	1.59 (1.09, 2.31)	1.47 (1.10, 1.96)	1.56 (0.93, 2.62)
Foot injury	n/a	1.52 (0.56, 4.13)	2.57 (1.18, 5.61)	1.17 (0.43, 3.19)	1.21 (0.55, 2.68)
No rOA at baseline	0.57 (0.21, 1.56)	n/a	n/a	n/a	n/a
rOA at baseline	1.60 (0.90, 2.84)	n/a	n/a	n/a	n/a

BMI = body mass index, NSAID = nonsteroidal anti-inflammatory drug, n/a = not applicable

Models adjusted for: race, work disability, NSAID use, any foot symptoms at baseline, and FAOS subscale at baseline.

**Supplementary Table.** Characteristics of participants with follow-up data (included in analysis) compared to those who did not return to the follow-up visit.

Characteristics	Returned to Follow-Up Visit	
	Yes (n=541)	No (n=323)
Baseline Age, mean±SD (years)	69.4±6.9	74.0±7.7
Women, n, %	382, 70.6%	207, 64.1%
Black, n, %	190, 35.1%	99, 30.7%
Baseline BMI, mean±SD (kg/m <sup>2</sup> )	31.2±6.4	30.2±6.2
NSAID use past 2 weeks, n, %	325, 60.1%	195, 60.4%
Work disability, n, %	119, 22.0%	87, 26.9%
History of gout, n, %	49, 9.1%	44, 13.6%
Prior foot injury, n, %	22, 4.1%	11, 3.4%
Foot joints with rOA:		
1 <sup>st</sup> metatarsophalangeal, n, %	55, 10.2%	33, 10.2%
1 <sup>st</sup> cuneometatarsal, n, %	11, 2.0%	10, 3.1%
2 <sup>nd</sup> cuneometatarsal, n, %	28, 5.2%	15, 4.6%
navicular-1 <sup>st</sup> cuneiform, n, %	33, 6.1%	17, 5.3%
talonavicular, n, %	36, 6.7%	24, 7.4%
Any foot symptoms	100, 18.5%	76, 23.5%
FAOS Symptoms, mean±SD	91.1±11.7	89.1±13.2
FAOS Pain, mean±SD	91.3±15.0	88.6±16.9
FAOS ADL, mean±SD	93.0±15.1	89.9±17.8
FAOS Sports and Recreation, mean±SD	83.9±27.6	75.4±35.0
FAOS QOL, mean±SD	86.6±20.8	82.7±22.9

SD=standard deviation; BMI=body mass index; NSAID=nonsteroidal anti-inflammatory drug; FAOS=Foot and Ankle Outcome Score